- Home
- CRIS vs PRTG Comparison
CRIS vs PRTG Comparison
Compare CRIS & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- PRTG
- Stock Information
- Founded
- CRIS 2000
- PRTG 1973
- Country
- CRIS United States
- PRTG British Virgin Islands
- Employees
- CRIS N/A
- PRTG N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- PRTG Oil & Gas Production
- Sector
- CRIS Health Care
- PRTG Energy
- Exchange
- CRIS Nasdaq
- PRTG Nasdaq
- Market Cap
- CRIS 21.3M
- PRTG 17.7M
- IPO Year
- CRIS 2000
- PRTG N/A
- Fundamental
- Price
- CRIS $1.63
- PRTG $5.42
- Analyst Decision
- CRIS Strong Buy
- PRTG
- Analyst Count
- CRIS 2
- PRTG 0
- Target Price
- CRIS $16.50
- PRTG N/A
- AVG Volume (30 Days)
- CRIS 130.8K
- PRTG 18.7K
- Earning Date
- CRIS 08-05-2025
- PRTG 08-26-2025
- Dividend Yield
- CRIS N/A
- PRTG N/A
- EPS Growth
- CRIS N/A
- PRTG N/A
- EPS
- CRIS N/A
- PRTG N/A
- Revenue
- CRIS $11,202,000.00
- PRTG N/A
- Revenue This Year
- CRIS N/A
- PRTG N/A
- Revenue Next Year
- CRIS $9.52
- PRTG N/A
- P/E Ratio
- CRIS N/A
- PRTG N/A
- Revenue Growth
- CRIS 14.17
- PRTG N/A
- 52 Week Low
- CRIS $1.02
- PRTG $2.10
- 52 Week High
- CRIS $8.29
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- CRIS 34.22
- PRTG 40.80
- Support Level
- CRIS $1.68
- PRTG $5.65
- Resistance Level
- CRIS $1.88
- PRTG $6.40
- Average True Range (ATR)
- CRIS 0.12
- PRTG 0.46
- MACD
- CRIS -0.01
- PRTG 0.03
- Stochastic Oscillator
- CRIS 17.14
- PRTG 10.90
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.